The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications.
 
Steven Maron
Stock and Other Ownership Interests - OneCell Diagnostics India
Honoraria - American Physician CME; Clarion Healthcare; Clinical Care Options; Medpage; MJH Healthcare Holdings, LLC; Oncoview; Physicans' Education Resource; Practicing Clinician Exchange; Vindico Medical Education
Consulting or Advisory Role - Amgen; Calcium; Elevation Oncology; Pinetree Therapeutics; Purple Biotech
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); PAIGE.AI (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Agenus (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Compugen (Inst); Cullinan Oncology (Inst); Debiopharm Group (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); IgM Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pliant (Inst); PureTech (Inst); Qualigen Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Ildefonso Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology
Consulting or Advisory Role - Cardinal Health; Syneos Health; Telix Pharmaceuticals; Werewolf Therapeutics
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint Biomedica; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
Speakers' Bureau - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; Thyme Care; TRACON Pharma
 
Alexander Philipovskiy
Research Funding - Abbvie (Inst); Agenus (Inst); Arvinas (Inst); Frontier Med (Inst); Immuneering (Inst); Inspirna (Inst); KAHR Medical (Inst); Monte Rosa Therapeutics (Inst); Valerio (Inst)
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Gerald Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Clinical Care Options
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); BridgeBio Pharma (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Sanofi (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); American Society of Clinical Oncology (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biomea Fusion (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Centessa Pharmaceuticals (Inst); Ciclomed (Inst); Conjupro Biotherapeutics (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); Eikon Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harbour BioMed (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kineta (Inst); Kolltan Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MD Anderson Cancer Center (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); National Institute of Health (NIH) (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); OncoMed (Inst); Oncorus (Inst); Oncothyreon (Inst); Phanes Therapeutics (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Roche (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tango Therapeutics (Inst); Tarus Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Ryan Hansen
Employment - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Patents, Royalties, Other Intellectual Property - Boundless Bio
 
Sara Weymer
Employment - Boundless Bio
Leadership - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Travel, Accommodations, Expenses - Boundless Bio
 
Klaus Wagner
Employment - Boundless Bio
Leadership - Boundless Bio
Stock and Other Ownership Interests - Boundless Bio
Patents, Royalties, Other Intellectual Property - Boundless Bio
 
Timothy Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amgen; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; BridGene Biosciences; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Debiopharm Group; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; FoRx Therapeutics; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Grey Wolf Therapeutics; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Joint scientific Committee for Phase I Trials in Hong Kong; Kyn therapeutics; Kyowa Kirin International; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; Prelude Therapeutics; ProLynx; Protai Bio; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); CPRIT; Cyteir (Inst); Department of Defense; EMD Serono (Inst); Exelixis; F-Star (Inst); Forbius (Inst); Genentech (Inst); Gilead Sciences; GlaxoSmithKline (Inst); Golfers Against Cancer; Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Pliant; Prelude Therapeutics; Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche; Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Synnovation; Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst); Zentalis